CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)

Sponsor: National Institutes of Health (NIH)
Due Date: July 20, 2020
Award: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Application budgets are not limited but must reflect the actual needs of the proposed project. Applications should rarely exceed $1,000,000 in direct costs per year unless during the optional clinical trial phase in which up to $1,500,000 in direct costs per year may be justified.

”